Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial

Radiotherapy and Oncology

Volumn 119, Issue 1, 2016, Pages 91-96

  Gomez Iturriaga, Alfonso ^a   Casquero, Francisco ^a   Urresola, Arantza ^b   Ezquerro, Ana ^b   Lopez, Jose I ^a   Espinosa, Jose M ^b   Minguez, Pablo ^b   Llarena, Roberto ^b   Irasarri, Ana ^a   Bilbao, Pedro ^a   Crook, Juanita ^c  

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Dominant intraprostatic lesion; Dose escalation; High Dose Rate brachytherapy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER STAGING; CHRONIC TOXICITY; CLINICAL ARTICLE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; IMAGE GUIDED RADIOTHERAPY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE VOLUME; RADIATION DOSE ESCALATION; RADIATION INJURY; RADIOTHERAPY DOSAGE; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; INTERVENTIONAL ULTRASONOGRAPHY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

AGED; BRACHYTHERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84958281140     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.02.004     Document Type: Article

References (41)

1. S.T.H. Peeters, W.D. Heemsbergen, P.C.M. Koper, W.L.J. van Putten, A. Slot, M.F.H. Dielwart, and et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 May 1 1990 1996
2. D.A. Kuban, S.L. Tucker, L. Dong, G. Starkschall, E.H. Huang, M.R. Cheung, and et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 Jan 1 67 74
3. V. Beckendorf, S. Guerif, E. Le Prisé, J.-M. Cosset, A. Bougnoux, B. Chauvet, and et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial Int J Radiat Oncol Biol Phys 80 2011 Jul 15 1056 1063
4. D.P. Dearnaley, M.R. Sydes, J.D. Graham, E.G. Aird, D. Bottomley, R.A. Cowan, and et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
5. A.L. Zietman, K. Bae, J.D. Slater, W.U. Shipley, J.A. Efstathiou, J.J. Coen, and et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09 J Clin Oncol 28 2010 Mar 1 1106 1111
6. N. Cellini, A.G. Morganti, G.C. Mattiucci, V. Valentini, M. Leone, S. Luzi, and et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 Jul 1 595 599
7. D. Pucar, H. Hricak, A. Shukla-Dave, K. Kuroiwa, M. Drobnjak, J. Eastham, and et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence Int J Radiat Oncol Biol Phys 69 2007 Sep 1 62 69
8. E. Arrayeh, A.C. Westphalen, J. Kurhanewicz, M. Roach, A.J. Jung, P.R. Carroll, and et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study Int J Radiat Oncol Biol Phys 82 2012 Apr 1 e787 e793
9. R. Miralbell, S.A. Roberts, E. Zubizarreta, and J.H. Hendry Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy Int J Radiat Oncol Biol Phys 82 2012 Jan 1 e17 e24
10. B. Turkbey, P.S. Albert, K. Kurdziel, and P.L. Choyke Imaging localized prostate cancer: current approaches and new developments Am J Roentgenol 192 2009 Jun 1471 1480
11. J.O. Barentsz, J. Richenberg, R. Clements, P. Choyke, S. Verma, G. Villeirs, and et al. ESUR prostate MR guidelines 2012 Eur Radiol 22 2012 Apr 746 757
12. D. Georg, J. Hopfgartner, J. Gòra, P. Kuess, G. Kragl, D. Berger, and et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 88 2014 Mar 1 715 722
13. Common Terminology Criteria for Adverse Events (CTCAE) - CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf [Internet]. [cited 2015 Aug 6]. Available from: < http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf >.
14. J.E. McNeal, H.M. Price, E.A. Redwine, F.S. Freiha, and T.A. Stamey Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance J Urol 139 1988 Jan 61 65
15. N.B. Delongchamps, F. Beuvon, D. Eiss, T. Flam, N. Muradyan, M. Zerbib, and et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer Prostate Cancer Prostatic Dis 14 2011 Sep 232 237
16. T. Okamura, Y. Umemoto, K. Yamashita, S. Suzuki, T. Shirai, Y. Hashimoto, and et al. Pitfalls with MRI evaluation of prostate cancer detection: comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens Urol Int 77 2006 301 306
17. V. Mouraviev, A. Villers, D.G. Bostwick, T.M. Wheeler, R. Montironi, and T.J. Polascik Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy BJU Int 108 2011 Oct 1074 1085
18. M. Karavitakis, H.U. Ahmed, P.D. Abel, S. Hazell, and M.H. Winkler Tumor focality in prostate cancer: implications for focal therapy Nat Rev Clin Oncol 8 2011 Jan 48 55
19. L. Marignol, M. Coffey, M. Lawler, and D. Hollywood Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 34 2008 Jun 313 327
20. B. Turkbey, H. Mani, V. Shah, A.R. Rastinehad, M. Bernardo, T. Pohida, and et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds J Urol 186 2011 Nov 1818 1824
21. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau, and L. Lemaitre Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings J Urol 176 2006 Dec 2432 2437
22. T.A. Stamey, J.E. McNeal, C.M. Yemoto, B.M. Sigal, and I.M. Johnstone Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 Apr 21 1395 1400
23. B.G. Hollmann, B. van Triest, G. Ghobadi, G. Groenendaal, J. de Jong, H.G. van der Poel, and et al. Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion Radiother Oncol 115 2015 Apr 96 100
24. G. Bauman, M. Haider, U.A. Van der Heide, and C. Ménard Boosting imaging defined dominant prostatic tumors: a systematic review Radiother Oncol 107 2013 Jun 274 281
25. E. Ippolito, G. Mantini, A.G. Morganti, E. Mazzeo, G.D.A. Padula, C. Digesù, and et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity Am J Clin Oncol 35 2012 Apr 158 162
26. W.W. Wong, S.E. Schild, S.A. Vora, G.A. Ezzell, B.D. Nguyen, P.C. Ram, and et al. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging Int J Radiat Oncol Biol Phys 81 2011 Nov 15 e423 e429
27. M. Pinkawa, C. Attieh, M.D. Piroth, R. Holy, S. Nussen, J. Klotz, and et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost Radiother Oncol 93 2009 Nov 213 219
28. A.K. Singh, P. Guion, N. Sears-Crouse, K. Ullman, S. Smith, P.S. Albert, and et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study Radiat Oncol Lond Engl 2 2007 36
29. R. Miralbell, M. Mollà, M. Rouzaud, A. Hidalgo, J.I. Toscas, J. Lozano, and et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study Int J Radiat Oncol Biol Phys 78 2010 Sep 1 50 57
30. R.J. Ellis, D.A. Kaminsky, E.H. Zhou, P. Fu, W.-D. Chen, A. Brelin, and et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer Int J Radiat Oncol Biol Phys 81 2011 Sep 1 29 34
31. S.J. DiBiase, K. Hosseinzadeh, R.P. Gullapalli, S.C. Jacobs, M.J. Naslund, G.N. Sklar, and et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 52 2002 Feb 1 429 438
32. P. Andrzejewski, P. Kuess, B. Knäusl, K. Pinker, P. Georg, J. Knoth, and et al. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy Radiother Oncol 2015 Sep 6
33. U. Schick, Y. Popowski, P. Nouet, S. Bieri, M. Rouzaud, H. Khan, and et al. High-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: hemi-irradiation of prostate cancer Prostate 71 2011 Sep 1309 1316
34. J. Pouliot, Y. Kim, E. Lessard, I.-C. Hsu, D.B. Vigneron, and J. Kurhanewicz Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging Int J Radiat Oncol Biol Phys 59 2004 Jul 15 1196 1207
35. J. Crook, A. Ots, M. Gaztañaga, M. Schmid, C. Araujo, M. Hilts, and et al. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion Brachytherapy 13 2014 Oct 433 441
36. L. Dickinson, H.U. Ahmed, C. Allen, J.O. Barentsz, B. Carey, J.J. Futterer, and et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging JMRI 37 2013 Jan 48 58
37. L.J. Murray, J. Lilley, C.M. Thompson, V. Cosgrove, J. Mason, J. Sykes, and et al. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions Int J Radiat Oncol 89 2014 Jun 406 415
38. E. Gibson, M. Gaed, J.A. Gómez, M. Moussa, C. Romagnoli, Z. Kassam, and et al. Toward prostate cancer contouring guidelines on mri: dominant lesion gross and clinical target volume coverage via accurate histology fusion Int J Radiat Oncol 90 2014 Sep S207
39. W.D. Foltz, A. Wu, P. Chung, C. Catton, A. Bayley, M. Milosevic, and et al. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer J Magn Reson Imaging JMRI 37 2013 Apr 909 916
40. I. Song, C.K. Kim, B.K. Park, and W. Park Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T AJR Am J Roentgenol 194 2010 Jun W477 W482
41. Y. Hu, H.U. Ahmed, Z. Taylor, C. Allen, M. Emberton, D. Hawkes, and et al. MR to ultrasound registration for image-guided prostate interventions Med Image Anal 16 2012 Apr 687 703